A Case Report of Colon Cancer Succeeding Long Survival Without Chemotherapy, Msi-H, Braf Mutated

Immunotherapy is now indicated in the first line setting in metastatic colon cancer, while it is generally indicated in MSI-H tumors. A similar BRAFm V600E mutation is a poor prognostic indicator, while there is approved treatment in the 2nd line. The tolerance profile of these treatments may be the same or even better compared to chemotherapy and their use has gained considerable priority. The aim with this report is to highlight the possibility of successfully treating a patient with metastatic colon cancer without chemotherapy in the first two lines, especially when it ought to a frail patient. The patient is monitored in our department from the beginning of her diagnosis until the moment of this publication.